In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Hold rating on HilleVax, Inc (HLVX – Research Report), with a price target of $2.00. Matthew Caufield has given his ...

HilleVax Inc.’s stock cratered 89% early Monday, after the biotech said it would discontinue development of a vaccine against norovirus for infants after a trial missed its main goals.

Shares of HilleVax plunged as much as 87.6% to a record low of $1.75 on Monday after the biotech company said it will discontinue the development of its norovirus vaccine candidate for infants.

Shares of HilleVax fell after the release of Phase 2b trial results for HIL-214, a vaccine for norovirus-related acute gastroenteritis in infants. The study showed 5% efficacy and no significant ...

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Hold rating on HilleVax, Inc (HLVX – Research Report). The associated price target remains the same with $2.00. Matthew Caufield ...

HIL-216 addresses six groups of norovirus viral strains, including the two covered by HIL-214. HilleVax has said it expects to begin Phase 1 testing of HIL-216 in late 2024.